Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125239 · ClinicalTrials.gov registry record · Phase 1
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Jacqueline Garcia, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03125239: Completed Phase 1 study, sponsored by Jacqueline Garcia, MD.
NCT03125239 is a Phase 1 study that has completed, run by Jacqueline Garcia, MD. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03125239, a Phase 1 study, has completed, sponsored by Jacqueline Garcia, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This research study is studying a combination of two targeted therapies as a possible treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did not fully respond. The name of the study interventions involved in this study are: * Merestinib * LY2874455
Primary Outcome
Dose-escalation will follow a standard 3+3 design exploring 3 dose levels of LY2874455 with a steady dose of Merestinib. We will escalate to next dose cohort if 0/3 or 1/6 participants have a DLT during the first cycle of therapy. If the rate of dose limiting toxicity (DLT) exceeds 30%, it is less likely that the dose of LY2874455 will be escalated.
Interventions
- DRUG Merestinib
- DRUG LY2874455
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 1 |
What the finished NCT03125239 record still lists
NCT03125239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Merestinib is the first listed.
NCT03125239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03125239 about?
NCT03125239 is a clinical study titled "Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia". This research study is studying a combination of two targeted therapies as a possible treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did not fully respond. The name of the study interventions involved in this study are: * Merestinib * LY2874455
What is the current status of trial NCT03125239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-08-10. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03125239?
The interventions under investigation include: Merestinib (DRUG), LY2874455 (DRUG).
Who is sponsoring clinical trial NCT03125239?
This trial is sponsored by Jacqueline Garcia, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03125239's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI